Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-13 12:28 pm Unchanged | 2025-03-31 | 13G | Aptose Biosciences Inc. APTO | Bleichroeder LP | 163,032 6.300% | 0 (Unchanged) | Filing History |
| 2025-03-24 6:48 pm Sale | 2025-03-24 | 13G | Aptose Biosciences Inc. APTO | Bleichroeder LP | 163,032 7.500% | -3,586,968 (-95.65%) | Filing History |
| 2025-03-21 7:14 pm Purchase | 2025-03-19 | 13G | Aptose Biosciences Inc. APTO | Bleichroeder LP | 3,750,000 6.200% | 3,625,000 (+2900.00%) | Filing History |
| 2025-03-20 8:54 pm Sale | 2025-03-18 | 13D | APTOSE BIOSCIENCES INC NO APTOF | Hanmi Pharmaceutical Co., Ltd. | 508,710 19.900% | -2,480,705 (-82.98%) | Filing History |
| 2025-02-14 4:57 pm Sale | 2024-12-31 | 13G | Aptose Biosciences Inc. APTO | Armistice Capital, LLC | 34,176 4.990% | -30,998 (-47.56%) | Filing History |
| 2025-02-13 8:26 pm Purchase | 2024-12-31 | 13G | Aptose Biosciences Inc. APTO | Bleichroeder LP | 125,000 6.200% | 125,000 (New Position) | Filing History |
| 2024-11-14 3:22 pm Purchase | 2024-09-30 | 13G | Aptose Biosciences Inc. APTO | Armistice Capital, LLC | 65,173 9.990% | 65,173 (New Position) | Filing History |
| 2024-04-26 12:54 pm Unchanged | 2024-04-24 | 13D | APTOSE BIOSCIENCES INC NO APTOF | Hanmi Pharmaceutical Co., Ltd. | 2,989,415 19.020% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:51 pm Sale | 2023-12-31 | 13G | APTOSE BIOSCIENCES INC NO APTOF | Nantahala Capital Management, LLC | 120,132 1.500% | -5,932,735 (-98.02%) | Filing History |
| 2024-02-02 6:05 pm Purchase | 2024-01-31 | 13D | APTOSE BIOSCIENCES INC NO APTOF | Hanmi Pharmaceutical Co., Ltd. | 2,989,415 22.170% | 2,105,263 (+238.11%) | Filing History |
| 2023-09-11 6:23 pm Purchase | 2023-09-06 | 13D | APTOSE BIOSCIENCES INC NO APTOF | Hanmi Pharmaceutical Co., Ltd. | 884,152 12.070% | 884,152 (New Position) | Filing History |
| 2023-02-14 4:56 pm Sale | 2022-12-31 | 13G | APTOSE BIOSCIENCES INC NO APTOF | Nantahala Capital Management, LLC | 6,052,867 6.600% | -1,551,826 (-20.41%) | Filing History |
| 2023-01-17 06:05 am Purchase | 2022-05-04 | 13G | APTOSE BIOSCIENCES INC NO APTOF | Fletcher Aaron G.L. | 6,246,788 6.770% | 6,246,788 (New Position) | Filing History |
| 2022-02-14 08:03 am Purchase | 2021-12-31 | 13G | APTOSE BIOSCIENCES INC NO APTOF | Nantahala Capital Management, LLC | 7,604,693 8.500% | 332,020 (+4.57%) | Filing History |
| 2022-02-11 4:15 pm Sale | 2021-12-31 | 13G | APTOSE BIOSCIENCES INC NO APTOF | OrbiMed Capital LLC | 0 0.000% | -8,030,000 (Position Closed) | Filing History |
| 2021-08-09 8:00 pm Purchase | 2021-08-03 | 13G | APTOSE BIOSCIENCES INC NO APTOF | Wilson Donald R. Jr. | 8,892,437 9.997% | 916,261 (+11.49%) | Filing History |
| 2021-02-17 3:05 pm Sale | 2020-12-31 | 13G | APTOSE BIOSCIENCES INC NO APTOF | Consonance Capital Management LP | 0 0.000% | -6,058,505 (Position Closed) | Filing History |
| 2021-02-16 4:09 pm Purchase | 2020-12-31 | 13G | APTOSE BIOSCIENCES INC NO APTOF | Consonance Capital Management LP | 6,058,505 11.000% | 6,058,505 (New Position) | Filing History |
| 2021-02-16 2:37 pm Sale | 2020-12-31 | 13G | APTOSE BIOSCIENCES INC NO APTOF | Consonance Capital Management LP | 0 0.000% | -4,772,190 (Position Closed) | Filing History |
| 2021-02-12 4:42 pm Purchase | 2020-12-31 | 13G | APTOSE BIOSCIENCES INC NO APTOF | OrbiMed Capital LLC | 8,030,000 9.040% | 8,030,000 (New Position) | Filing History |